Rejuveron lands $75m to advance healthy aging portfolio; expands focus in Middle East

Rejuveron lands $75m to advance healthy aging portfolio; expands focus in Middle East

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Longevity biotech opens strategic Abu Dhabi office as Mubadala Capital joins Series B investment round.

Longevity biotech company Rejuveron Life Sciences has successfully closed a dual-tranche Series B equity and convertible loan financing round, raising a total of $75 million. The funding was co-led by Catalio Capital Management and Apeiron Investment Group, the family office and private investment firm of entrepreneur Christian Angermayer. The round was also joined by new investor Mubadala Capital, a subsidiary of Mubadala Investment Company, the $280 billion sovereign investor group headquartered in Abu Dhabi, UAE.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Danny Sullivan

Danny has worked in technology communications for more than 20 years, and has been writing about developments the longevity sector since 2019. With a keen interest in the transfer of technology to market, he focuses primarily on the companies working on cutting-edge solutions to aging and age-related diseases.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Oyster surfaces with $60m and a tau degrader that travels light

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE